Drug Trial Radar · NCT07479862
A Study of SA030 Injection in Overweight/Obese Participants With or Without Type 2 Diabetes Mellitus (T2DM)
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Apr 16, 2026
Primary completion
Apr 24, 2028
Study completion Apr 24, 2028
Sponsor
- Lead sponsor
- Suzhou Siran Biotechnology Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is the first time the study drug, SA030, is being given to people. The main goal of this study is to find out if it is safe, how well people can tolerate it, how the body processes the drug, how the drug works, and whether it causes any immune reactions. The study has two parts. In Part 1, people who are overweight or have obesity will receive a single dose of the drug, starting with a low dose and slowly increasing it. In Part 2, people with obesity (with or without type 2 diabetes) will receive multiple doses over time. SA030 is being developed as a potential new treatment for people who are overweight or have obesity. Over the last few decades, more and more people around the world have become overweight or obese, and the numbers keep rising in almost every country. From 1990 to 2021, this problem grew steadily and reached its highest point in 2021.
Conditions
- Obese
- Overweight
- T2DM (Type 2 Diabetes Mellitus)
Interventions
SA030 InjectionDrug
Single dose, 5 dose levels; mulitple dose, 3 dose levels or 2 dose levels
Matching PlaceboDrug
Single dose, matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: Approximatly 12 months
- Number of participants with clinical significant laboratory abnormalitiesTime frame: Approximatly 12 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research Pty Ltd North Terrace
Adelaide, Australia · Recruiting
Nucleus Network
Brisbane, Queensland, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.